BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Exclusion Criteria

• •Lymphocyte predominant nodular Hodgkin's lymphoma
• •Prior treatment with brentuximab vedotin
• •Female patient who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug
• •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol.
• •Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
• •Symptomatic neurologic disease compromising normal activities of daily living or requiring medic
• •Any sensory or motor peripheral neuropathy greater than or equal to Grade 2
• •Known history of any of the following cardiovascular conditions defined in the protocol
• •Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose
• •Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives (or 28 days if the half-lives are unknown) of last dose of that prior treatment
• •Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.
• •Known human immunodeficiency virus (HIV) positive
• •Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
• •Focal radiation therapy within 30 days prior to study recruitment
• •Major surgery within 28 days prior to randomization
• •Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease.
• •Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.